Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension

Physiological Reports

Volumn 1, Issue 7, 2013, Pages

  Ogawa, Aiko ^a   Firth, Amy L ^b   Ariyasu, Sanae ^c   Yamadori, Ichiro ^c   Matsubara, Hiromi ^a   Song, Shanshan ^d   Fraidenburg, Dustin R ^d   Yuan, Jason X J ^d  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Akt signaling; Chronic thromboembolic pulmonary hypertension; Pulmonary hypertension; Store operated calcium entry; Thrombin

Indexed keywords

CALCIUM; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 1; RAPAMYCIN; THROMBIN; THYMIDINE;

ARTICLE; BLOOD CLOTTING; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; DNA SYNTHESIS; DOWNSTREAM PROCESSING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID SCINTILLATION COUNTING; NORMAL HUMAN; PHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY OCCLUSION; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; THROMBOEMBOLISM; THROMBOSIS; THYMIDINE INCORPORATION ASSAY; TRANSIENT EXPRESSION; VASCULAR REMODELING; WESTERN BLOTTING;

EID: 85008895558     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.190     Document Type: Article

References (55)

1. Agard, C., M. Rolli-Derkinderen, E. Dumas-de-La-Roque, M. Rio, C. Sagan, J. P. Savineau, et al. 2009. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br. J. Pharmacol. 158:1285-1294.
2. Auger, W. R., P. F. Fedullo, K. M. Moser, M. Buchbinder, and K. L. Peterson. 1992. Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. Radiology 182:393-398.
3. Auger, W. R., K. M. Kerr, N. H. Kim, and P. F. Fedullo. 2012. Evaluation of patients with chronic thromboembolic pulmonary hypertension for pulmonary endarterectomy. Pulm Circ 2:155-162.
4. Brown, E. J., M. W. Albers, T. B. Shin, K. Ichikawa, C. T. Keith, W. S. Lane, et al. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756-758.
5. Burrowes, K. S., A. R. Clark, and M. H. Tawhai. 2011. Blood flow redistribution and ventilation-perfusion mismatch during embolic pulmonary arterial occlusion. Pulm Circ 1:365-376.
6. Calleja, V., M. Laguerre, P. J. Parker, and B. Larijani. 2009. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol. 7:e17.
7. Chung, S. W., J. W. Park, S. A. Lee, S. K. Eo, and K. Kim. 2010. Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell. Biochem. Biophys. Res. Commun. 396:748-754.
8. Coughlin, S. R. 2000. Thrombin signalling and protease-activated receptors. Nature 407:258-264.
9. Dartevelle, P., E. Fadel, S. Mussot, A. Chapelier, P. Herve, M. de Perrot, et al. 2004. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 23:637-648.
10. Datta, S. R., A. Brunet, and M. E. Greenberg. 1999. Cellular survival: a play in three Akts. Genes Dev. 13:2905-2927.
11. Di Nisio, M., S. Middeldorp, and H. R. Buller. 2005. Direct thrombin inhibitors. N. Engl. J. Med. 353:1028-1040.
12. Edinger, A. L., C. M. Linardic, G. G. Chiang, C. B. Thompson, and R. T. Abraham. 2003. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63:8451-8460.
13. Firth, A. L., J. Yau, A. White, P. G. Chiles, J. J. Marsh, T. A. Morris, et al. 2009. Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 296:L979-L986.
14. Firth, A. L., W. Yao, A. Ogawa, M. M. Madani, G. Y. Lin, and J. X. Yuan. 2010. Multipotent mesenchymal progenitor cells are present in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Am. J. Physiol. Cell Physiol. 298:C1217-C1225.
15. Ghigliotti, G., A. R. Waissbluth, C. Speidel, D. R. Abendschein, and P. R. Eisenberg. 1998. Prolonged activation of prothrombin on the vascular wall after arterial injury. Arterioscler. Thromb. Vasc. Biol. 18:250-257.
16. Gorlach, A., R. S. BelAiba, J. Hess, and T. Kietzmann. 2005. Thrombin activates the p21-activated kinase in pulmonary artery smooth muscle cells. Role in tissue factor expression. Thromb. Haemost. 93:1168-1175.
17. Goruppi, S., E. Ruaro, and C. Schneider. 1996. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12:471-480.
18. Hauck, R. W., C. Schulz, A. Schomig, R. K. Hoffman, and R. A. Panettieri. 1999. Alpha-thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors. Am. J. Physiol. 277:L22-L29.
19. Hisamoto, K., M. Ohmichi, H. Kurachi, J. Hayakawa, Y. Kanda, Y. Nishio, et al. 2001. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol. Chem. 276:3459-3467.
20. Houssaini, A., S. Abid, N. Mouraret, F. Wan, D. Rideau, M. Saker, et al. 2013. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 48:568-577.
21. Humar, R., F. N. Kiefer, H. Berns, T. J. Resink, and E. J. Battegay. 2002. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16:771-780.
22. Hunter, R. W., C. Mackintosh, and I. Hers. 2009. Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J. Biol. Chem. 284:12339-12348.
23. Kwapiszewska, G., P. Markart, B. K. Dahal, B. Kojonazarov, L. M. Marsh, R. T. Schermuly, et al. 2012. PAR-2 inhibition reverses experimental pulmonary hypertension. Circ. Res. 110:1179-1191.
24. Li, F. and K. U. Malik. 2005. Angiotensin II-induced Akt activation is mediated by metabolites of arachidonic acid generated by CaMKII-stimulated Ca2+-dependent phospholipase A2. Am J Physiol Heart Circ Physiol 288: H2306-H2316.
25. Liu, X. B., J. Jiang, C. Gui, X. Y. Hu, M. X. Xiang, and J. A. Wang. 2008. Angiopoietin-1 protects mesenchymal stem cells against serum deprivation and hypoxia-induced apoptosis through the PI3K/Akt pathway. Acta Pharmacol. Sin. 29:815-822.
26. Madamanchi, N. R., S. Li, C. Patterson, and M. S. Runge. 2001. Thrombin regulates vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway. J. Biol. Chem. 276:18915-18924.
27. Mangi, A. A., N. Noiseux, D. Kong, H. He, M. Rezvani, J. S. Ingwall, et al. 2003. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9:1195-1201.
28. McNamara, C. A., I. J. Sarembock, L. W. Gimple, J. W. 2nd Fenton, S. R. Coughlin, and G. K. Owens. 1993. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 91:94-98.
29. Morales-Ruiz, M., M. J. Lee, S. Zollner, J. P. Gratton, R. Scotland, I. Shiojima, et al. 2001. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J. Biol. Chem. 276:19672-19677.
30. Morgensztern, D. and H. L. McLeod. 2005. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797-803.
31. Moser, K. M. and C. M. Bloor. 1993. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 103:685-692.
32. Nagata, K., K. Ohashi, T. Nakano, H. Arita, C. Zong, H. Hanafusa, et al. 1996. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J. Biol. Chem. 271:30022-30027.
33. Nakano, T., K. Higashino, N. Kikuchi, J. Kishino, K. Nomura, H. Fujita, et al. 1995. Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca2+-mobilizing growth factors. J. Biol. Chem. 270:5702-5705.
34. Ogawa, A., A. L. Firth, W. Yao, M. M. Madani, K. M. Kerr, W. R. Auger, et al. 2009. Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L666-L676.
35. Ozsu, S. and H. Cinarka. 2013. Chronic thromboembolic pulmonary hypertension: medical treatment. Pulm Circ 3:341-344.
36. Paddenberg, R., P. Stieger, A. L. von Lilien, P. Faulhammer, A. Goldenberg, H. H. Tillmanns, et al. 2007. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir. Res. 8:15.
37. Pawlinski, R., M. Tencati, C. R. Hampton, T. Shishido, T. A. Bullard, L. M. Casey, et al. 2007. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 116:2298-2306.
38. Pengo, V., Lensing, A. W., M. H. Prins, A. Marchiori, B. L. Davidson, F. Tiozzo, et al., and Thromboembolic Pulmonary Hypertension Study G. 2004. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350:2257-2264.
39. Pietra, G. G., W. D. Edwards, J. M. Kay, S. Rich, J. Kernis, B. Schloo, et al. 1989. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80:1198-1206.
40. Sacks, R. S., C. V. Remillard, N. Agange, W. R. Auger, P. A. Thistlethwaite, and J. X. Yuan. 2006. Molecular biology of chronic thromboembolic pulmonary hypertension. Semin. Thorac. Cardiovasc. Surg. 18:265-276.
41. Sacks, R. S., A. L. Firth, C. V. Remillard, N. Agange, J. Yau, E. A. Ko, et al. 2008. Thrombin-mediated increases in cytosolic [Ca2+] involve different mechanisms in human pulmonary artery smooth muscle and endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 295:L1048-L1055.
42. Sakao, S., H. Hao, N. Tanabe, Y. Kasahara, K. Kurosu, and K. Tatsumi. 2011. Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respir. Res. 12:109.
43. Schmitt, J. M., G. A. Wayman, N. Nozaki, and T. R. Soderling. 2004. Calcium activation of ERK mediated by calmodulin kinase I. J. Biol. Chem. 279:24064-24072.
44. Schror, K., E. Bretschneider, K. Fischer, J. W. Fischer, R. Pape, B. H. Rauch, et al. 2010. Thrombin receptors in vascular smooth muscle cells-function and regulation by vasodilatory prostaglandins. Thromb. Haemost. 103: 884-890.
45. Schulman, S., C. Kearon, A. K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, et al., et al., and Group R-CS. 2009. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361:2342-2352.
46. Shah, B. H. and K. J. Catt. 2002. Calcium-independent activation of extracellularly regulated kinases 1 and 2 by angiotensin II in hepatic C9 cells: roles of protein kinase Cdelta, Src/proline-rich tyrosine kinase 2, and epidermal growth receptor trans-activation. Mol. Pharmacol. 61: 343-351.
47. Smyth, S. S., D. S. Woulfe, J. I. Weitz, C. Gachet, P. B. Conley, S. G. Goodman, et al., and Platelet Colloquium Participants. 2009. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler. Thromb. Vasc. Biol. 29:449-457.
48. Takahashi, S. and M. E. Mendelsohn. 2003. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J. Biol. Chem. 278:30821-30827.
49. Vivanco, I. and C. L. Sawyers. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2:489-501.
50. Vogel, S. M., X. Gao, D. Mehta, R. D. Ye, T. A. John, P. Andrade-Gordon, et al. 2000. Abrogation of thrombin-induced increase in pulmonary microvascular permeability in PAR-1 knockout mice. Physiol. Genomics 4:137-145.
51. Vu, T. K., D. T. Hung, V. I. Wheaton, and S. R. Coughlin. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068.
52. Wu, S. Q. and W. C. Aird. 2005. Thrombin, TNF-a, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 289:H873-H885.
53. Wu, S., J. Haynes Jr, J. T. Taylor, B. O. Obiako, J. R. Stubbs, M. Li, et al. 2003. Cav3.1 (a1G) T-type Ca2+ channels mediate vaso-occlusion of sickled erythrocytes in lung microcirculation. Circ. Res. 93:346-353.
54. Xiang, B., G. Zhang, J. Liu, A. J. Morris, S. S. Smyth, T. K. Gartner, et al. 2010. A Gi-independent mechanism mediating Akt phosphorylation in platelets. J. Thromb. Haemost. 8:2032-2041.
55. Yao, W., A. L. Firth, R. S. Sacks, A. Ogawa, W. R. Auger, P. F. Fedullo, et al. 2009. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 296:L870-L878.